BioN­Tech pays $20M up­front for two mon­o­clon­al an­ti­bod­ies from Chi­na's WuXi Bi­o­log­ics

BioN­Tech is pay­ing out $20 mil­lion up­front to an­oth­er Chi­nese part­ner in ex­change for the rights to de­vel­op two pre­clin­i­cal mon­o­clon­al an­ti­bod­ies, this time with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.